Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.72EUR
14 Aug 2018
Change (% chg)

€0.23 (+0.31%)
Prev Close
€73.49
Open
€73.56
Day's High
€73.85
Day's Low
€73.48
Volume
193,224
Avg. Vol
2,660,788
52-wk High
€86.39
52-wk Low
€62.88

Select another date:

Fri, Aug 10 2018

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Sanofi has been stockpiling drugs for no-deal Brexit - WSJ

French drugmaker Sanofi has been making drug-shortage contingency plans for more than a year to prepare for Britain and the European Union failing to reach a Brexit transition deal, the Wall Street Journal reported on Tuesday, citing a source. | Video

Sanofi stockpiling in UK in case of Brexit no-deal - statement

PARIS, Aug 1 Sanofi on Wednesday said it had made arrangements for additional warehouse capacity in Britain to stockpile products, as it makes contingency plans for a no-deal in Brexit negotiations.

Sanofi has been stockpiling drugs for no-deal Brexit: WSJ

French drugmaker Sanofi has been making drug-shortage contingency plans for more than a year to prepare for Britain and the European Union failing to reach a Brexit transition deal, the Wall Street Journal reported on Tuesday, citing a source.

Sanofi has been stockpiling drugs for no-deal Brexit - WSJ

July 31 French drugmaker Sanofi has been making drug-shortage contingency plans for more than a year to prepare for Britain and the European Union failing to reach a Brexit transition deal, the Wall Street Journal reported on Tuesday, citing a source.

Genzyme rare disease drug sales drive Sanofi profit

PARIS Strong sales growth at Sanofi's Genzyme rare diseases business drove better than expected second quarter profit, allowing the French drugmaker to narrow its 2018 target.

UPDATE 3-Genzyme rare disease drug sales drive Sanofi profit

* 2018 EPS growth now expected between 3 and 5 percent (Adds Dupixent figures, shares, comment)

Genzyme sales help Sanofi deliver Q2 stable earnings

PARIS, July 31 Sanofi posted slightly higher-than-expected second-quarter profits on the back of strong sales growth at its key rare diseases Genzyme unit, and narrowed its 2018 profit target.

Sanofi halts production at Pyrenees plant after pollution complaint

PARIS Drugmaker Sanofi has stopped production at a plant in the French Pyrenees after an environment body filed a complaint against what it said was massive air pollution.

UPDATE 1-Sanofi halts production at Pyrenees plant after pollution complaint

* Complaint lodged by France Nature Environnement (Recasts on production being halted)

Select another date: